Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023631 | 0.94 | LMNA (0.39) | LMNASMN1; SMN2KMT2AMEN1ECE1 | |
| SCHEMBL7025592 | 0.94 | LMNA (0.38) | LMNASMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL7029993 | 0.93 | LMNA (0.37) | LMNASMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL7025743 | 0.92 | KMT2A (0.39) | LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7024985 | 0.90 | SMN1; SMN2 (0.39) | LMNASMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL7069790 | 0.87 | LMNA (0.39) | LMNASMN1; SMN2KMT2AMEN1ECE1 | |
| SCHEMBL7028093 | 0.87 | LMNA (0.37) | LMNASMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL7026780 | 0.86 | KMT2A (0.41) | LMNASMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL7029121 | 0.85 | KMT2A (0.38) | LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7073956 | 0.85 | KMT2A (0.38) | LMNASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229228-A1 | Novel alpha-sulfin-and alpha-sulfonamino acid amides | SYNGENTA CROP PROTECTION, INC. | 2003-12-11 | — | — | US | disclosed |
| EP-1274678-A1 | NOVEL ALPHA-SULFIN- AND ALPHA-SULFONAMIDO ACID AMIDES | Syngenta Participations AG (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001079159-A1 | NOVEL α-SULFIN- AND α-SULFONAMINO ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229228-A1 | Novel alpha-sulfin-and alpha-sulfonamino acid amides | ARSA, STS, CBR1 | LMNA 4568/4885SMN1; SMN2 1574/4885KMT2A 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.